TLR4 and breast carcinoma: Importantly, as previously noted, hyperoside can enhance the sensitivity of breast cancer cells to the conventional chemotherapy drug paclitaxel, an effect mediated by the inhibition of pro-inflammatory and pro-survival mechanisms associated with TLR4 activation (Sun et al., 2020).